

Igni18, a novel metallo-hydrolase from the hyperthermophilic archaeon *Ignicoccus hospitalis* KIN4/I: cloning, expression, purification and X-ray analysis

Stefanie Kobus,^a Pablo Perez-Garcia,^b Astrid Hoepfner,^a Nicholas Holzschek,^b Filip Kovacic,^c Wolfgang R. Streit,^b Karl-Erich Jaeger,^{c,d} Jennifer Chow^b and Sander H. J. Smits^{a,e,*}

Received 28 September 2018

Accepted 25 February 2019

Edited by M. J. Romao, Universidade Nova de Lisboa, Portugal

Keywords: *Ignicoccus hospitalis*; α/β -hydrolases; metallo- β -lactamases.

Supporting information: this article has supporting information at journals.iucr.org/f


^aCenter for Structural Studies (CSS), Heinrich Heine University Düsseldorf, Universitätsstrasse 1, 40225 Düsseldorf, Germany, ^bDepartment of Microbiology and Biotechnology, University of Hamburg, Ohnhorststrasse 18, 22609 Hamburg, Germany, ^cInstitute of Molecular Enzyme Technology (IMET), Heinrich Heine University Düsseldorf, 52426 Jülich, Germany, ^dInstitute of Bio- and Geosciences IBC-1: Biotechnology, Forschungszentrum Jülich GmbH, 52426 Jülich, Germany, and ^eInstitute of Biochemistry, Heinrich Heine University Düsseldorf, Universitätsstrasse 1, 40225 Düsseldorf, Germany. *Correspondence e-mail: sander.smits@hhu.de

The hyperthermophilic crenarchaeon *Ignicoccus hospitalis* KIN4/I possesses at least 35 putative genes encoding enzymes that belong to the α/β -hydrolase superfamily. One of those genes, the metallo-hydrolase-encoding *igni18*, was cloned and heterologously expressed in *Pichia pastoris*. The enzyme produced was purified in its catalytically active form. The recombinant enzyme was successfully crystallized and the crystal diffracted to a resolution of 2.3 Å. The crystal belonged to space group *R*32, with unit-cell parameters $a = b = 67.42$, $c = 253.77$ Å, $\alpha = \beta = 90.0$, $\gamma = 120.0^\circ$. It is suggested that it contains one monomer of Igni18 within the asymmetric unit.

1. Introduction

Ignicoccus hospitalis KIN4/I is an anaerobic, hyperthermophilic crenarchaeon with an optimal growth temperature of 90°C (363 K). It was isolated from a submarine hydrothermal system at the Kolbeinsey Ridge in the north of Iceland (Paper *et al.*, 2007). The archaeon belongs to the order Desulfurococcales and is an obligate chemolithoautotroph that grows by performing sulfur reduction using hydrogen as the electron donor. Among other uncommon metabolic pathways, *I. hospitalis* utilizes a rare autotrophic CO₂-fixation pathway starting from acetyl-coenzyme A (Jahn *et al.*, 2007). With 1.3 Mbp coding for 1444 proteins, it has one of the smallest genomes described for a free-living organism (Podar *et al.*, 2008). It is also the only organism known to date that is capable of acting as a host for *Nanoarchaeum equitans*, which is so far the only cultivated member of the Nanoarchaeota (Paper *et al.*, 2007; Huber *et al.*, 2000). This is the only natural archaeon–archaeon interaction that has been described *in vivo* (Wrede *et al.*, 2012), although it remains unclear whether it is a true mutualistic symbiosis or parasitism (Jahn *et al.*, 2008). Owing to the small genome size of *N. equitans* (0.5 Mbp), *I. hospitalis* provides the biological macromolecules that it cannot synthesize owing to a lack of essential biosynthesis pathways such as those for lipids, amino acids and nucleotides (Waters *et al.*, 2003) and even energetic precursors (Giannone *et al.*, 2011, 2015).

Living at above 90°C requires adaptation of all enzymes in order to carry out the metabolic reactions that are necessary



for existence. The amino-acid composition, especially a decrease in thermolabile residues such as asparagine and cysteine, hydrophobic interactions, aromatic interactions, ion pairs and increased salt-bridge networks, oligomerization and intersubunit interactions, packing and reduction of solvent-exposed surface area, flexibility of surface-exposed loops, and metal binding or substrate stabilization are some of the factors that have been attributed to confer protein stability at extreme temperatures (Unsworth *et al.*, 2007; Kovacic *et al.*, 2016).

Enzymes that belong to the α/β -hydrolase superfamily include metabolically important enzymes that carry out a large number of different hydrolysis and synthesis reactions. The metallo- β -lactamase (MBL) subfamily includes enzymes that hydrolyze thiol-ester, phosphodiester and sulfuric ester bonds, but also includes oxidoreductases. Many members of this subfamily are involved in mRNA maturation and DNA repair (Bebrone, 2007). The presence of MBL genes within the Eubacteria, Archaea and Eukaryota suggests a very ancient origin of this family (Garau *et al.*, 2005). The first crystal structure of an archaeal metallo- β -lactamase was published in 2010 (ST1585 from *Sulfolobus tokodaii*; Shimada *et al.*, 2010). MBL enzymes usually show a characteristic $\alpha\beta/\beta\alpha$ protein fold and are often dependent on Zn^{2+} ions (Meini *et al.*, 2015).

To date, only four crystal structures of native *I. hospitalis* proteins are available: a cell-adhesion structural protein (PDB entry 3j1r; Yu *et al.*, 2012), a membrane-associated octaheme cytochrome *c* (PDB entry 4q05; Parey *et al.*, 2016), the type IV pilus-like filament protein Iho670 (PDB entry 5kyh; Braun *et al.*, 2016) and a superoxide reductase (PDB entry 4bk8; Romão *et al.*, 2018). Here, we present the recombinant production, purification and crystallization of an MBL-like domain-containing protein from *I. hospitalis* KIN4/I.

2. Materials and methods

2.1. Cloning and overexpression

The *igni18* gene (NCBI accession No. IGNI_RS06455; start nucleotide No. 1115579, end nucleotide No. 1114878), which has been annotated as a metallo-hydrolase containing a metallo- β -lactamase fold (Podar *et al.*, 2008), was amplified with Phusion High-Fidelity DNA Polymerase (ThermoFisher Scientific, Carlsbad, California, USA) from *I. hospitalis* KIN4/I genomic DNA kindly donated by Dr Harald Huber (University of Regensburg, Germany). The EasySelect *Pichia* Expression Kit (Invitrogen, Carlsbad, California, USA) was employed for cloning and expression. The oligonucleotides designed for the amplification of *igni18* (Table 1) allowed the hydrolysis of the PCR product with EcoRI and NotI and cloning into the pPICZ-A expression plasmid (Invitrogen) using *Escherichia coli* DH5 α . The start of the gene was modified to include a Kozak consensus sequence for yeast [5'-(G/A)NNATGG-3'; Romanos *et al.*, 1992] and the stop codon was omitted for fusion with a C-terminal Myc epitope and His₆ tag encoded by the vector sequence. These allow immunodetection and affinity-chromatographic purification of the produced fusion protein.

Table 1
Igni18 production information.

Source organism	<i>I. hospitalis</i> KIN4/I
DNA source	<i>I. hospitalis</i> KIN4/I
Forward primer† (5'–3')	CCGAGAAATTC GACA TGCCACGGTTAAGCTGACCTAC
Reverse primer† (5'–3')	AGCGGCCGCAAAATTCGAAGGTCACCGTCTCC
Cloning and expression vector	pPICZ-A
Cloning host	<i>E. coli</i> DH5 α
Expression host	<i>P. pastoris</i> X-33
Igni18_Myc_His ₆ amino-acid sequence	MATVKLTYFGHSFAFHVVDGVIADPWITNPLSKTTLEDYLNKFKTDLVVI THAHEDHIGDALEIMRRTGAKFFSIHEIYVDLTQKGFQIGANIGGPAKLDDVAPGLGIALT PATHSSYDKGVPTGAIIFKDGKALVYHAGDTGLFAEMQFIGELYAPKVALLPIGGHYTMIDIEQALLATKLLRPEVVVPMHYNTFPPIRADPNEFKQKVESAGLAKVRVMEPEGETVTTFEFCGRQLGPEQKLI SEEDLN SAVDHHHHHH

† Restriction sites are underlined and modifications are in bold.

The constructed pPICZ-A::*igni18* expression vector purified from *E. coli* DH5 α was linearized with MssI restriction endonuclease (ThermoFisher Scientific) prior to electroporation of *Pichia pastoris* X-33 competent host cells (Invitrogen) according to the manual. Insertion into the chromosome occurs via homologous recombination at the 5' AOX1 (alcohol oxidase 1) region. Colonies carrying the construct appeared on YPD–agar plates containing 1 M sorbitol and 100 $\mu\text{g ml}^{-1}$ zeocin (Invitrogen) after 3–5 d of incubation at 303 K. The clones were tested for multiple insertions of the construct by the ability to grow on YPD–agar containing 1 mg ml^{-1} zeocin. A total of eight multi-insertion clones were tested for expression, and the production of the protein fused with a His₆ tag was verified by Western blotting using anti-His₆-tag-specific antibodies as described in the manual (Invitrogen). The clone yielding the highest Igni18 production was selected. It showed the methanol-utilization slow (Mut^S) phenotype, in which one of the copies of pPICZ-A::*igni18* replaced the original AOX1 locus, creating a mutant that can assimilate methanol only at slow rates. Fermentation was performed in 1.5 l buffered extra-YNB glycerol methanol (BYGM) auto-induction medium (Lee *et al.*, 2017) in a fermenter (Minifors, INFORS AG, Bottmingen, Switzerland) for 45 h at 303 K. Glycerol is used as the preferable carbon source for initial growth. After 24 h, the glycerol is consumed and methanol induces the expression of the gene of interest. The cells were harvested by centrifugation and the cell pellet was stored at 193 K until further use. Macromolecule-production information is summarized in Table 1.

2.2. Protein purification and enzyme-activity assays

For immobilized metal ion-affinity chromatography (IMAC) purification of Igni18_Myc_His₆, the cells were thawed on ice and suspended in 5 ml lysis buffer [10 mg ml^{-1} myristyl sulfobetaine (SB3-14), 1 mM phenylmethylsulfonyl fluoride (PMSF), 0.05 M NaH_2PO_4 , 0.3 M NaCl pH 8.0] per gram. Cell disruption and partial purification were achieved by

Table 2
Crystallization conditions.

Method	Sitting-drop vapor diffusion
Plate type	MRC3, Swissci
Temperature (K)	293
Protein concentration (mg ml ⁻¹)	20
Buffer composition of protein solution	0.1 M potassium phosphate pH 7
Composition of reservoir solution	0.3 M magnesium nitrate hexahydrate, 0.1 M Tris pH 8, 22%(w/v) PEG 8000
Volume and ratio of drop	200 nl, 1:1
Volume of reservoir (μl)	40

incubating the cells at 343 K for 1 h in the presence of the zwitterionic detergent SB3-14 (Zanna & Haeuw, 2007). Cell debris was removed from the crude cell extract by centrifugation at 15 000 rev min⁻¹ for 30 min at 277 K (Sorvall RC6+ centrifuge, SS-34 rotor; Thermo Scientific, Braunschweig, Germany). The clear lysate was loaded onto a Protino Ni-TED 2000 Packed Column (Macherey-Nagel, Düren, Germany) and Igñi18 was purified according to the manufacturer's instructions. The buffer of the elution fractions was exchanged to 0.1 M potassium phosphate buffer pH 7.0 using an ultra-filtration unit with a pore size of 10 kDa (Vivaspin 20, Sartorius AG, Göttingen, Germany). The proteins were analyzed by polyacrylamide gel electrophoresis under denaturing conditions (SDS-PAGE) on 12%(w/v) gels stained with Coomassie Brilliant Blue G-250 (Laemmli, 1970) and by Western blotting (Fig. 1). Activity was assayed on *para*-nitrophenyl (*p*NP) esters with fatty-acid chain lengths ranging from two to 18 C atoms (Jaeger & Kovacic, 2014).

2.3. Crystallization and preliminary X-ray analysis of Igñi18

Crystallization trials were performed using the sitting-drop vapor-diffusion method at 293 and 285.15 K. To find an initial




Figure 1
Ni-TED affinity purification of Igñi18_Myc_His₆ (SDS-PAGE, left; Western blot, right). The samples were mixed with a loading dye containing 0.1 M dithiothreitol and were partially denatured at 368 K (95°C) for 10 min. Lane M, protein molecular-weight marker (PageRuler Unstained Protein Ladder, Thermo Scientific, Braunschweig, Germany; labeled in kDa); lane 1, lysate; lane 2, flowthrough; lane 3, initial column wash; lane 4, final column wash; lane E, elution fraction; lane PM, prestained protein molecular-weight marker (PageRuler Prestained Protein Ladder, Thermo Scientific, Braunschweig, Germany; labeled in kDa). Bands corresponding to monomeric Igñi18 and oligomers are marked with dots and were confirmed by Western blot analysis using His₆-specific antibodies.

crystallization condition, various commercial kits from Qiagen (Hilden, Germany) and Molecular Dimensions (Suffolk, England) were used in MRC3 Swissci plates.

0.1 μl of homogenous recombinant Igñi18 (at either 15 or 20 mg ml⁻¹ in 0.1 M potassium phosphate buffer pH 7) was mixed with 0.1 μl reservoir solution and equilibrated against 40 μl reservoir solution using a pipetting robot (NT8, Formulatrix, Bedford, Massachusetts, USA).

Crystals were grown at room temperature and reached final dimensions of around 130 × 90 × 80 μm after several months (Fig. 2a). The crystallization condition consisted of 0.3 M magnesium nitrate hexahydrate, 0.1 M Tris pH 8, 22%(w/v) PEG 8000. To verify that the crystals contained protein, a fluorescence image was obtained using the intrinsic fluorescence of the tryptophan residue present in the Igñi18 protein (Fig. 2b). The crystal was cryoprotected by overlaying the drop with 2 μl mineral oil and subsequently flash-cooled in liquid nitrogen. Crystallization information is summarized in Table 2.

2.4. Data collection and processing

A data set was collected from a single Igñi18 crystal on beamline ID30A-3 at the European Synchrotron Radiation Facility (ESRF), Grenoble, France at 100 K. Initially, four frames were taken for characterization with 0.5° rotation at angles of 0°, 45°, 90° and 135°. The images were processed and a strategy was calculated using *BEST* (Bourenkov & Popov, 2010). A data set was then collected based on this strategy, resulting in the use of 0.05° rotation per frame with a total of 2500 frames (a total of 125° rotation). This data set was initially processed using the automated processing pipeline at the ID30A-3 beamline and was subsequently reprocessed using *XDS* (Kabsch, 2010), *XSCALE* and *POINTLESS* (Evans, 2006) to determine the space group. Data-collection and processing statistics are summarized in Table 3. To check for anomalous signal, the data were separately processed such that the Friedel pairs remained unmerged.




Figure 2
Crystal of Igñi18. Visible image (a) and UV image (b) of an Igñi18 crystal obtained in 0.3 M magnesium nitrate hexahydrate, 0.1 M Tris pH 8, 22%(w/v) PEG 8000.

Table 3
Data collection and processing.

Values in parentheses are for the highest resolution shell.

X-ray source	ID30A-3, ESRF, Grenoble
Detector	EIGER 4M
Wavelength (Å)	0.9677
Temperature (K)	100
Crystal-to-detector distance (mm)	118.16
Rotation range per image (°)	0.05
Total rotation range (°)	125
Exposure time (s)	0.002
Space group	<i>R</i> 32
<i>a</i> , <i>b</i> , <i>c</i> (Å)	67.42, 67.42, 253.77
α , β , γ (°)	90.0, 90.0, 120.0
Resolution range (Å)	31.32–2.30 (2.382–2.300)
Total reflections	70412 (7119)
Unique reflections	10293 (1008)
R_{merge}	0.1004 (0.5445)
R_{meas}	0.1084 (0.5872)
$R_{\text{p.i.m.}}$	0.03987 (0.2152)
$CC_{1/2}$	0.998 (0.885)
Wilson <i>B</i> factor (Å ²)	32.46
$\langle I/\sigma(I) \rangle$	12.60 (3.37)
Completeness (%)	99.78 (100.00)
Multiplicity	6.8 (7.1)
Matthews coefficient (Å ³ Da ⁻¹)	2.17
Solvent content (%)	43.4

3. Results and discussion

A *BLASTp* search (Altschul *et al.*, 2005) against the GenBank nonredundant database indicated that enzymes similar to Igni18 can only be found within the genus *Ignicoccus* with 78% identity. Furthermore, less similar enzymes with an identity of 52% or lower mostly belong to other members of the Crenarchaeota. The physiological function of this lipase and putative metallo-hydrolase in the respective hyperthermophilic organisms needs to be elucidated. To date, only about 61% of the protein-coding genes within *I. hospitalis* KIN4/I have bioinformatically predicted functions, implying that many pathways within this archaeon as well as its symbiont *N. equitans* are still unknown.

Initial attempts to produce the metallo-hydrolase Igni18 in different *E. coli* strains failed (data not shown); therefore, we used the yeast *P. pastoris* carrying multiple chromosomally integrated copies of the *igni18* gene as an expression system. It seems that some of the problems regarding translation and post-translational modifications of the archaeal protein can be circumvented by using the eukaryotic *P. pastoris* compared with *E. coli*. After purification by affinity chromatography on Ni-TED agarose, the purity of Igni18_Myc_His₆ was estimated to be greater than 90% and the yield was approximately 8 mg per litre of expression culture. The purified Igni18_Myc_His₆ monomer has an apparent molecular weight of 30 kDa, which is in good agreement with the theoretical value of 28 614 Da (Fig. 1). The native protein seems to occur in an oligomeric state and this complex is highly stable, as expected from the nature of its native host; it can be denatured only partially with a reducing loading dye and heat incubation for 10 min at 368 K (95°C). Using a Western blot immunodetection method, the three bands could be identified as His₆-tagged Igni18 (Fig. 1). Under semi-native running conditions, *i.e.* SDS-PAGE with nonreducing loading dye and without

prior heat denaturation, only one single band could be observed on the gel at slightly below 130 kDa (data not shown). This suggests that native, soluble Igni18 predominantly exists in a multimeric form.

The enzyme activity of Igni18 was confirmed on *p*NP esters. Further assays are required with lipase-specific and MBL-specific substrates and need to be performed to reveal the precise biochemical function of Igni18. The optimal enzymatic activity of Igni18 was determined as 363 K (90°C), which corresponds to the optimal growth temperature of the host organism (Pérez-García *et al.*, unpublished work).

The purified Igni18 was used to screen for suitable crystallization conditions using different commercial screening kits from Qiagen (Hilden, Germany) and Molecular Dimensions (Suffolk, England) and an NT8 pipetting robot (Formulatrix). Only a few Igni18 crystals appeared after several months in a condition consisting of 0.3 M magnesium nitrate hexahydrate, 0.1 M Tris pH 8, 22% (*w/v*) PEG 8000. Although the crystallization condition was further optimized by grid screening, only the crystal obtained in the initial screen displayed diffraction quality suitable for the collection of a data set.

From this crystal, which diffracted to beyond 2.0 Å resolution (Fig. 3), a complete data set was collected on beamline ID30A-3 at the ESRF, Grenoble, France to a resolution of 2.3 Å. Here, we cut the data owing to incompleteness at higher resolutions. Preliminary X-ray diffraction analysis showed that the Igni18 crystal belonged to the hexagonal space group *R*32, with unit-cell parameters *a* = *b* = 67.42, *c* = 253.77 Å, α = β = 90.0, γ = 120.0°. Calculation of the unit-cell volume indicated the presence of one monomer in the asymmetric unit with a




Figure 3
Diffraction image of an Igni18 crystal with a resolution of 1.7 Å at the edge of the detector (indicated by the black circle).

calculated V_M of $2.17 \text{ \AA}^3 \text{ Da}^{-1}$ and a solvent content of 43.4% (Matthews, 1968).

Interestingly, the anomalous signal after processing using *XDS* and *XSCALE* revealed the presence of an anomalous scatterer in the protein crystal, which was likely to result from endogenously bound metal within the Igni18 protein. Since Igni18 is a metallo-hydrolase, this suggests that this anomalous scatterer was bound to the protein directly during expression. Using the anomalous scattering analysis server (<http://skuld.bmsc.washington.edu/scatter/>), we analyzed which scatterer might be present. At the used wavelength of 0.9677 \AA , we assume that manganese, iron, cobalt, nickel, copper and zinc might be possible candidates. They display scattering coefficients f' or f'' which range from 1.4 e for manganese to 3.9 e for iron. Since we did not add any of these ions to the buffers or the protein, we cannot precisely tell which one was bound by the Igni18 protein. By sequence homology, this protein belongs to the archaeal metallo- β -lactamase family, suggesting that it would be functional with zinc. However, we used a nickel column during purification, so this also might be the bound scatterer. Initial substructure analysis using *AutoSol* as part of the *PHENIX* suite (Adams *et al.*, 2010) indicates that two atoms are bound within the asymmetric unit, suggesting, in combination with the Matthews coefficient, that one monomer has two anomalous scatterers bound. We used *Auto-Rickshaw* (Panjikar *et al.*, 2009) to obtain the initial phases using the MR-SAD option, supplying only the Igni18 protein sequence as model input, which resulted in an initial model which is currently being refined. Although a monomer is present in the asymmetric unit, a trimeric Igni18 protein is likely to be built by the threefold axes given by the *R32* symmetry. This suggests that despite the presence of only one monomer in the asymmetric unit the Igni18 protein crystallized as an oligomeric protein. The electron density is of good quality and allowed the entire sequence of Igni18 to be fitted unambiguously (see Supplementary Fig. S1).

Acknowledgements

X-ray diffraction measurements were performed on beamline ID30A-3 at the European Synchrotron Radiation Facility (ESRF), Grenoble, France. We are grateful to Guillaume Gotthard at the ESRF for providing assistance in using beamline ID30A-3. We thank Dr Harald Huber, University of Regensburg, Germany for providing us with genomic DNA of *I. hospitalis*. This project was partially funded by the Horizon2020 project INMARE (Grant agreement ID: 634486).

References

Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., McCoy, A. J., Moriarty, N. W., Oeffner, R., Read, R. J., Richardson, D. C., Richardson, J. S., Terwilliger, T. C. & Zwart, P. H. (2010). *Acta Cryst. D* **66**, 213–221.

Altschul, S. F., Wootton, J. C., Gertz, E. M., Agarwala, R., Morgulis, A., Schäffer, A. A. & Yu, Y.-K. (2005). *FEBS J.* **272**, 5101–5109.

Bebrone, C. (2007). *Biochem. Pharmacol.* **74**, 1686–1701.

Bourenkov, G. P. & Popov, A. N. (2010). *Acta Cryst. D* **66**, 409–419.

Braun, T., Vos, M. R., Kalisman, N., Sherman, N. E., Rachel, R., Wirth, R., Schoeder, G. F. & Egelman, E. H. (2016). *Proc. Natl Acad. Sci. USA*, **113**, 10352–10357.

Evans, P. (2006). *Acta Cryst. D* **62**, 72–82.

Garau, G., Di Guilmi, A. M. & Hall, B. G. (2005). *Antimicrob. Agents Chemother.* **49**, 2778–2784.

Giannone, R. J., Huber, H., Karpinets, T., Heimerl, T., Küper, U., Rachel, R., Keller, M., Hettich, R. L. & Podar, M. (2011). *PLoS One*, **6**, e22942.

Giannone, R. J., Wurch, L. L., Heimerl, T., Martin, S., Yang, Z., Huber, H., Rachel, R., Hettich, R. L. & Podar, M. (2015). *ISME J.* **9**, 101–114.

Huber, H., Burggraf, S., Mayer, T., Wyszchony, I., Rachel, R. & Stetter, K. O. (2000). *Int. J. Syst. Evol. Microbiol.* **50**, 2093–2100.

Jaeger, K. E. & Kovacic, F. (2014). *Methods Mol. Biol.* **1149**, 111–134.

Jahn, U., Gallenberger, M., Paper, W., Junglas, B., Eisenreich, W., Stetter, K. O., Rachel, R. & Huber, H. (2008). *J. Bacteriol.* **190**, 1743–1750.

Jahn, U., Huber, H., Eisenreich, W., Hügler, M. & Fuchs, G. (2007). *J. Bacteriol.* **189**, 4108–4119.

Kabsch, W. (2010). *Acta Cryst. D* **66**, 125–132.

Kovacic, F., Mandrysch, A., Poojari, C., Strodel, B. & Jaeger, K. E. (2016). *Protein Eng. Des. Sel.* **29**, 65–76.

Laemmli, U. K. (1970). *Nature (London)*, **227**, 680–685.

Lee, J. Y., Chen, H., Liu, A., Alba, B. M. & Lim, A. C. (2017). *Protein Expr. Purif.* **137**, 7–12.

Matthews, B. W. (1968). *J. Mol. Biol.* **33**, 491–497.

Meini, M.-R., Llarrull, L. I. & Vila, A. J. (2015). *FEBS Lett.* **589**, 3419–3432.

Panjikar, S., Parthasarathy, V., Lamzin, V. S., Weiss, M. S. & Tucker, P. A. (2009). *Acta Cryst. D* **65**, 1089–1097.

Paper, W., Jahn, U., Hohn, M. J., Kronner, M., Näther, D. J., Burghardt, T., Rachel, R., Stetter, K. O. & Huber, H. (2007). *Int. J. Syst. Evol. Microbiol.* **57**, 803–808.

Parey, K., Fielding, A. J., Sörgel, M., Rachel, R., Huber, H., Ziegler, C. & Rajendran, C. (2016). *FEBS J.* **283**, 3807–3820.

Podar, M., Anderson, I., Makarova, K. S., Elkins, J. G., Ivanova, N., Wall, M. A., Lykidis, A., Mavromatis, K., Sun, H., Hudson, M. E., Chen, W., Deciu, C., Hutchison, D., Eads, J. R., Anderson, A., Fernandes, F., Szeto, E., Lapidus, A., Kyrpides, N. C., Saier, M. H. Jr, Richardson, P. M., Rachel, R., Huber, H., Eisen, J. A., Koonin, E. V., Keller, M. & Stetter, K. O. (2008). *Genome Biol.* **9**, R158.

Romanos, M. A., Scorer, C. A. & Clare, J. J. (1992). *Yeast*, **8**, 423–488.

Romão, C. V., Matias, P. M., Sousa, C. M., Pinho, F. G., Pinto, A. F., Teixeira, M. & Bandejas, T. M. (2018). *Biochemistry*, **57**, 5271–5281.

Shimada, A., Ishikawa, H., Nakagawa, N., Kuramitsu, S. & Masui, R. (2010). *Proteins*, **78**, 2399–2402.

Unsworth, L. D., van der Oost, J. & Koutsopoulos, S. (2007). *FEBS J.* **274**, 4044–4056.

Waters, E., Hohn, M. J., Ahel, I., Graham, D. E., Adams, M. D., Barnstead, M., Beeson, K. Y., Bibbs, L., Bolanos, R., Keller, M., Kretz, K., Lin, X., Mathur, E., Ni, J., Podar, M., Richardson, T., Sutton, G. G., Simon, M., Söll, D., Stetter, K. O., Short, J. M. & Noordewier, M. (2003). *Proc. Natl Acad. Sci. USA*, **100**, 12984–12988.

Wrede, C., Dreier, A., Kokoschka, S. & Hoppert, M. (2012). *Archaea*, **2012**, 596846.

Yu, X., Goforth, C., Meyer, C., Rachel, R., Wirth, R., Schröder, G. F. & Egelman, E. H. (2012). *J. Mol. Biol.* **422**, 274–281.

Zanna, L. & Haeuw, J. F. (2007). *J. Chromatogr. B*, **846**, 368–373.